

SYSTEMATIC REVIEW

Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials

EVA HEILMANN^{1,2}, CLAUDIA GREGORIANO^{1,2}, DJILLALI ANNANE³, KONRAD REINHART^{4,5}, LILA BOUADMA⁶, MICHEL WOLFF⁶, JEAN CHASTRE⁶, CHARLES-EDOUARD LUYT⁷, FLORENCE TUBACH⁸, ANGELA R. BRANCHE⁹, MATTHIAS BRIEL¹⁰, MIRJAM CHRIST-CRAIN¹¹, TOBIAS WELTE¹², CASPAR CORTI¹³, EVELIEN DE JONG¹⁴, MAARTEN NIJSTEN¹⁵, DYLAN W. DE LANGE¹⁶, JOS A.H. VAN OERS¹⁷, ALBERTUS BEISHUIZEN¹⁸, ARMAND R. J. GIRBES¹⁴, RODRIGO O. DELIBERATO¹⁹, STEFAN SCHROEDER²⁰, KRISTINA B. KRISTOFFERSEN²¹, NATHALIE LAYIOS²², PIERRE DAMAS²², STELLA S. S. LIMA²³, VANDACK NOBRE²³, LONG WEI²⁴, CAROLINA F. OLIVEIRA²³, YAHYA SHEHABI^{25,26}, DAIANA STOLZ²⁷, MICHAEL TAMM²⁷, ALESSIA VERDURI²⁸, JIN-XIANG WANG²⁹, SABINE DREVET³⁰, GAETAN GAVAZZI³⁰, BEAT MUELLER^{1,31}, PHILIPP SCHUETZ^{1,31}

¹Medical University Department, Kantonsspital Aarau, Aarau, Switzerland

²Department of Oncology, Kantonsspital Aarau, Aarau, Switzerland

³Department of Critical Care, Hyperbaric Medicine and Home Respiratory Unit, Center for Neuromuscular Diseases, Raymond Poincaré Hospital (AP-HP), Garches, France

⁴Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany

⁵Clinical Trial Centre Leipzig, University of Leipzig, Leipzig, Germany

⁶Service de Réanimation Médicale, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris 7-Denis-Diderot, Paris, France

⁷Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France

⁸Département d'Epidémiologie Biostatistique et Recherche Clinique, AP-HP, Hôpitaux Universitaires Paris Nord Val de Seine, Paris, France

⁹Department of Medicine, Rochester General Hospital, New York, NY, USA

¹⁰Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland

¹¹Division of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Basel, Basel, Switzerland

¹²Department of Pulmonary Medicine, Medizinische Hochschule Hannover, Hannover, Germany

¹³Department of Respiratory Medicine, Hospital Bispebjerg, Copenhagen University, Copenhagen, Denmark

¹⁴Department of Intensive Care, VU University Medical Center, Amsterdam, the Netherlands

¹⁵University Medical Centre, University of Groningen, Groningen, the Netherlands

¹⁶University Medical Center Utrecht, Utrecht, the Netherlands

¹⁷Department of Intensive Care Medicine, Elisabeth Tweesteden Hospital, Tilburg, the Netherlands

¹⁸Medisch Spectrum Twente, Enschede, the Netherlands

¹⁹Critical Care Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil

²⁰Department of Anesthesiology and Intensive Care Medicine, Krankenhaus Dueren, Dueren, Germany

²¹Department of Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark

²²Department of General Intensive Care, University Hospital of Liege, Domaine Universitaire de Liège, Liege, Belgium

²³Department of Internal Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil

²⁴Department of Medicine, Shanghai Fifth People's Hospital, Shanghai, China

²⁵Critical Care and Peri-operative Medicine, Monash Health, Melbourne, Australia

²⁶Faculty of Medicine Nursing and Health Sciences, School of Clinical Sciences, Monash University, Melbourne, Australia

²⁷Clinic of Pneumology and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland

²⁸Department of Medical and Surgical Sciences, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy

²⁹Department of Respiratory and Critical Care Medicine, Beijing Luhe Hospital, Capital Medical University, Beijing, China

³⁰University Clinics of Geriatrics, University Hospital of Grenoble-Alpes, GREPI TIMC-IMAG CNRS 5525 University of Grenoble Alpes, Grenoble, France

³¹Faculty of Medicine, University of Basel, Basel, Switzerland

Address correspondence to: Philipp Schuetz, University Department of Medicine, Kantonsspital Aarau, Tellstrasse, CH-5001 Aarau, Switzerland. Tel: +41 (0) 62 838 41 41. Email: schuetzph@gmail.com

Abstract

Background: Older patients have a less pronounced immune response to infection, which may also influence infection biomarkers. There is currently insufficient data regarding clinical effects of procalcitonin (PCT) to guide antibiotic treatment in older patients.

Objective and design: We performed an individual patient data meta-analysis to investigate the association of age on effects of PCT-guided antibiotic stewardship regarding antibiotic use and outcome.

Subjects and methods: We had access to 9,421 individual infection patients from 28 randomized controlled trials comparing PCT-guided antibiotic therapy (intervention group) or standard care. We stratified patients according to age in four groups (<75 years [$n = 7,079$], 75–80 years [$n = 1,034$], 81–85 years [$n = 803$] and >85 years [$n = 505$]). The primary endpoint was the duration of antibiotic treatment and the secondary endpoints were 30-day mortality and length of stay.

Results: Compared to control patients, mean duration of antibiotic therapy in PCT-guided patients was significantly reduced by 24, 22, 26 and 24% in the four age groups corresponding to adjusted differences in antibiotic days of -1.99 (95% confidence interval [CI] -2.36 to -1.62), -1.98 (95% CI -2.94 to -1.02), -2.20 (95% CI -3.15 to -1.25) and -2.10 (95% CI -3.29 to -0.91) with no differences among age groups. There was no increase in the risk for mortality in any of the age groups. Effects were similar in subgroups by infection type, blood culture result and clinical setting (P interaction >0.05).

Conclusions: This large individual patient data meta-analysis confirms that, similar to younger patients, PCT-guided antibiotic treatment in older patients is associated with significantly reduced antibiotic exposures and no increase in mortality.

Keywords: age, older patients, procalcitonin, antibiotic stewardship

Key Points

- PCT-guided antibiotic treatment significantly reduced antibiotic exposures in older patients without increasing mortality in older patients.
- PCT-guided antibiotic treatment did not lead to higher mortality in older patients.
- Despite differences in the immune response in older patients, a biomarker strategy to guide antibiotic treatment is feasible.

Introduction

Sepsis remains a major healthcare problem worldwide and is responsible for a large number of deaths particularly in the older patient population [1, 2]. Early identification and appropriate initial management, including start of antibiotic treatment and fluid resuscitation, have been shown to improve outcomes [2, 3]. In addition, monitoring of patients during treatment both for timely escalation of therapy in case of treatment failure and de-escalation in case of a favourable treatment response has an important impact on patients' recovery [2]. This also includes early de-escalation or cessation of antibiotic treatment once a patient's condition has stabilized, with signs indicating progression towards resolution of infection. In addition to closely monitoring the clinical status of patients, blood biomarkers mirroring

specific physiopathological pathways may help to better estimate the resolution of infection thereby improving clinical decision-making [4–6]. Serum procalcitonin (PCT) has emerged as a host-derived biomarker that provides prognostic information in patients with infections and thus may improve sepsis management [7, 8]. Particularly, the kinetics of PCT in an infected patient provide information about the recovery and risk for adverse outcome, which in turn may influence decisions about the duration of antibiotic treatment [7–9]. Multiple randomized controlled trials (RCT) have investigated the benefits of using serum PCT levels to guide whether and for how long antibiotic therapy is used—a process referred to as PCT-guided antibiotic stewardship—in patients with different types of infections including sepsis patients in intensive care unit (ICU) [1, 10–20]. There are several trials and meta-analyses from such trials suggesting

E. Heilmann *et al.*

that PCT use decreases antibiotic exposure with beneficial effects on clinical outcomes including lower mortality in patients with respiratory tract infections, sepsis and blood stream infection [21–25].

Still, it remains unclear whether data from these trials are also true for older patients who might have a different cytokine and biomarker response to infection compared to younger patients [26, 27]. Older patients may have often impairment in kidney function, which may affect biomarker kinetics, but has not been shown to impact on PCT-guided stewardship efforts in a previous analysis [28]. Also, older patients have a less pronounced immune response to infection and important differences in regard to the adaptive and innate immunity have been well documented [26]. As a result, older patients may not present with fever and clinical signs of inflammation/infection compared to younger patients, but their mortality risk associated with infection and sepsis is much higher compared to younger patients [29, 30]. This also may impact the clinical interpretation of different biomarkers of infection in this group of patients. There is an important lack of conclusive evidence on the efficacy and safety of PCT for antibiotic stewardship across different age groups [31]. Previous individual trials have had limited statistical power regarding different age subgroups. In addition, traditional aggregate data meta-analyses have been inconclusive as no age stratification was possible [32, 33].

To address this significant drawback of earlier meta-analyses and to understand whether patient age would have an influence on the efficacy and safety of PCT protocols to guide antibiotic treatment, we did a secondary analysis of a previously published meta-analysis of individual patient data from 28 RCTs in patients with different types and severities of infection stratified in four different age groups. The main finding of the meta-analysis regarding effects of PCT use in patients with respiratory infections has been published previously [22, 34], as well as other analyses looking specifically at specific subgroups of patients with sepsis [21] and patients with positive blood cultures [35], and associations of admission kidney function on PCT use [28]. We contacted the authors of 28 RCTs identified in the earlier meta-analysis [22, 34] in order to obtain their original datasets. We analysed these datasets in the current study to determine whether PCT-guided therapy was associated with a change in duration of antibiotic therapy specifically in the >75-year-old age group.

Methods

Role of funding source

The initial Cochrane analysis received funding from the National Institute for Health Research and several included trials received funding from industry regarding free-of-charge kits for measurement of PCT. For this study, an unrestricted grant was provided by Thermo-Fisher Scientific. This was an investigator-initiated study and Thermo-Fisher Scientific had no bearing on study design, data collection,

data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Patient population and trial selection

We used an existing individual patient database from 2017 [21–23, 34–37] and updated the underlying search in February 2018 but did not find new trials which could have been included. We performed a secondary meta-analysis focusing on PCT-guided antibiotic therapy in older patients. Study selection and data collection were done according to the original protocol published in the Cochrane Library [25], and the report was prepared following the Preferred Reporting Items for Systematic Review and Meta-Analysis individual participant data guidelines [38, 39]. Individual patient data were extracted from 28 RCTs including patients with proven or suspected infection treated in three different settings (ICU, medical ward and primary care) and whose age was documented. Consequently, according to the initial protocol, trials lacking information regarding patient age were excluded from analysis as well as paediatric trials and those not using a PCT algorithm to guide antibiotic therapy. There was no information regarding frailty available in trials.

Search strategy and selection criteria

In collaboration with the Cochrane collaboration, the trial search was updated in February 2018 and undertaken in all databases from the date of their inception to February 2018. Overall, databases searched included the Cochrane Central Register for Controlled Trials (January 2017, Issue 1), Medline Ovid (1966 to February 2017) and Embase (1980 to February 2017). All references were screened for eligibility, and there were no language or publication restrictions. Based on titles, abstracts and full-text reports, two authors Yannick Wirz (Bürgerspital Solothurn, Switzerland) and Marc A. Meier (Triemli Spital, Zuerich, Switzerland) independently assessed eligibility of the trials. As needed, further information was directly obtained from investigators. In case of eligibility, study protocols, case report forms and unedited databases containing individual patient data were requested from investigators. Data from each trial were checked against reported results and queries were resolved with the principal investigator, trial data manager or statistician. Across all trials, data were rated in a uniform manner with standard definitions and parameters. Thus, mortality rates differed slightly from previous reports. To assess the risk of selection bias, performance bias, detection bias, attrition bias, reporting bias and other types of bias, we used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) [40] in accordance with the Cochrane methodology and have published detailed information risk of bias previously [22]. The grading was done by two authors (Y.W. and M.A.M.) and if needed discussed with another author (P.S.) and within the meta-analysis group.

Patients and endpoints

In our final meta-analysis, we included patients suffering from proven or suspected infection whose age was known and who had been enrolled in a previous trial being randomized either to PCT-guided therapy or to a control group.

The primary endpoint was the duration of antibiotic treatment (in days). Secondary endpoints included 30-day mortality and length of hospital and ICU stay within 30 days of randomization. In case of a shorter follow-up period, the available information in the trials was used (e.g. mortality at the time of hospital discharge).

To assess the effect of PCT guidance in older people and in accordance with the diversity of older people, patients were divided into four different age subgroups. Patients younger than 75 years were classified as young-olds, patients >85 years were classified as old-olds and patients between 75 and 85 years of age were classified as middle-olds and further divided into a group of 75–80 years and 81–85 years.

Statistical analysis

All statistical analyses were done using STATA version 15.1 (StataCorp., College Station, TX). Following the statistical approach of the previously published Cochrane Library study protocol with additional stratification according to age, we used multivariable hierarchical logistic regression [41, 42] to analyse the association between primary and secondary outcomes and age, type of infection, treatment arm and treatment setting, which were reported as odds ratios (ORs) and 95% confidence intervals (CIs). A 'trial' variable was added to the model as a random effect in order to control for within- and between-trial variability. Corresponding linear and logistic regression models were adapted for continuous and binary secondary endpoints, respectively. According to the intention-to-treat principle, patients were analysed in the groups to which they initially were randomly assigned. Additional predefined subgroup analyses were performed for type of infection, blood culture results, treatment setting (ICU, medical ward, primary care) and the level of organ dysfunction (Sequential Organ Failure Assessment [SOFA]).

Results

Systemic research and characteristics of included trials

Study flowchart is presented in [Figure 1](#). The initial study search identified a total of 990 records, 71 of which were assessed for eligibility and 32 of which in turn were potentially eligible for the analysis. Overall, we excluded four trials because individual data were not available from the authors. Within the remaining 28 trials, we excluded 11 patients due to missing information regarding patient age. Thus, our final analysis encompasses 9,421 individual patient records included in 28 RCTs.

[Appendix 1](#), available in *Age and Ageing* online, gives an overview about the 28 included trials that were performed in 12 different countries, including Australia, Belgium, Brazil, China, Denmark, France, Germany, Italy, Serbia, Switzerland, the Netherlands and the USA. Thirteen trials were multicentric, 14 trials were performed in the ICU setting, 12 in the emergency department or medical ward and 2 were from primary care. The three largest trials were the SISPECT trial ($n = 1,089$) [11], the ProHOSP trial ($n = 1,359$) [24] and the SAPS trial ($n = 1,516$) [13]. All trials had a somewhat similar concept regarding the use of PCT with recommendations to initiate, continue or stop antibiotic treatment based on the PCT values on admission and during follow-up. Also, all trials have used highly sensitive PCT assays with a functional assay sensitivity of 0.06 µg/l (Kryptor PCT; Brahms, Hennigsdorf, Germany) and an assay time of less than 20 minutes to measure PCT in order to have optimal sensitivity and thus test performance. A detailed analysis regarding PCT algorithms used in the trials has been published previously [43].

Bias assessment regarding allocation concealment, blinded outcome assessment, number of patients with follow-up data for mortality and adherence to the PCT algorithm of the included trials is presented in [Appendix 2](#), available in *Age and Ageing* online. Most trials had allocation concealment with central randomization and high follow-up for mortality. Only few trials had blinded outcome assessment. Adherence was variable among trials with 12 trials showing adherence to the PCT algorithm of more than 70% and 9 with lower than 70% (mostly ICU trials). In seven trials, adherence was not reported.

Baseline characteristics

[Appendix 3](#), available in *Age and Ageing* online, shows baseline characteristics of included patients stratified according to randomization overall, and in the four age groups (<75 years [$n = 7,079$], 75–80 years [$n = 1,034$], 81–85 years [$n = 803$] and >85 years [$n = 505$]). Groups were well balanced regarding sociodemographic (age, gender), PCT levels, severity of illness and type of infection. The most common infection focus was the respiratory tract. Patients in the highest age group (>85 years) were less frequently included in ICU trials compared to younger patients.

Primary endpoint: duration of antibiotic treatment

[Table 1](#) shows the primary endpoint (duration of antibiotic treatment) overall and again stratified by age groups and within subgroups. Overall, PCT-guided patients ($n = 4,714$) had a significantly lower mean duration of antibiotic treatment compared to control patients ($n = 4,707$) of 6.5 days versus 8.5 days (adjusted difference -2.01 days, [95% CI -2.32 to -1.69]). The effects of PCT use were different among different patient groups with more pronounced reduction of treatment duration in patients with respiratory tract infections, but the effects were similar among the different age groups overall (P for interaction 0.654) and




Figure 1. Study flowchart.

within the subgroups (Table 1 and Figure 2). As a sensitivity analysis, in a first step, we also included age as a continuous variable into the model and did not find evidence for effect modification of age on the association of PCT use and lower antibiotic treatment durations (P for interaction 0.644).

In a second step, we performed subgroup analysis of age to look for any old age-specific changes, which, however, also revealed to have no effect modification.

Secondary endpoint: mortality

Table 2 shows data about mortality overall, stratified by age group and stratified by age group within the different subgroups. Overall by 30 days, there were 543 deaths in 4,714 PCT-guided patients (11.5%) compared to 599 deaths in 4,707 control-group patients (12.7%), resulting in an

adjusted OR for overall mortality of 0.90 (95% CI 0.81–1.00, $P = 0.046$). Effects on mortality were similar in all age groups with no evidence for effect modification (P for interaction 0.891) (Figure 3). The same was true also for all subgroups stratified by infection diagnosis, blood culture results, setting and sepsis severity. As a sensitivity analysis, we also included age as a continuous variable into the model and again did not find evidence for effect modification of age on the association of PCT use and mortality (P for interaction 0.507).

Secondary endpoint: length of stay

We found no significant difference regarding length of hospital stay as well as length of ICU stay in intervention compared to control group patients (overall 17.9 ± 23.5

Table 1. Primary endpoint (duration of antibiotic therapy [days]) overall and stratified by age, diagnosis, blood culture results, setting and sepsis severity

	Control (no. of Control group)	PCT (no. of PCT group)	Adjusted regression coefficient* (95% CI), <i>P</i> value	<i>P</i> for interaction
Antibiotic therapy [days], mean ± SD				
Subgroups by age				
Overall	(<i>n</i> = 4,707), 8.5 ± 8.2	(<i>n</i> = 4,714), 6.5 ± 7.8	-2.01 (-2.32, -1.69), <i>P</i> < 0.001	
Age <75 years	(<i>n</i> = 3,551), 8.4 ± 8.3	(<i>n</i> = 3,528), 6.4 ± 8.1	-1.99 (-2.36, -1.62), <i>P</i> < 0.001	0.654
Age 75–80 years	(<i>n</i> = 500), 9.2 ± 8.8	(<i>n</i> = 534), 7.2 ± 7.4	-1.98 (-2.94, -1.02), <i>P</i> < 0.001	
Age 80–85 years	(<i>n</i> = 405), 8.8 ± 7.0	(<i>n</i> = 398), 6.5 ± 7.1	-2.20 (-3.15, -1.25), <i>P</i> < 0.001	
Age >85 years	(<i>n</i> = 251), 8.6 ± 7.8	(<i>n</i> = 254), 6.5 ± 6.0	-2.10 (-3.29, -0.91), <i>P</i> < 0.001	
Subgroups by diagnosis				
<i>Pneumonia</i>				
Overall	(<i>n</i> = 974), 10.3 ± 5.7	(<i>n</i> = 962), 6.6 ± 5.1	-3.71 (-4.19, -3.24), <i>P</i> < 0.001	
Age <75 years	(<i>n</i> = 655), 10.2 ± 6.0	(<i>n</i> = 607), 6.3 ± 5.2	-3.89 (-4.51, -3.28), <i>P</i> < 0.001	0.555
Age 75–80 years	(<i>n</i> = 96), 10.9 ± 6.4	(<i>n</i> = 118), 7.5 ± 5.6	-3.51 (-5.13, -1.88), <i>P</i> < 0.001	
Age 80–85 years	(<i>n</i> = 117), 10.2 ± 4.0	(<i>n</i> = 114), 7.2 ± 4.9	-3.03 (-4.19, -1.87), <i>P</i> < 0.001	
Age >85 years	(<i>n</i> = 106), 10.4 ± 4.2	(<i>n</i> = 123), 6.5 ± 4.5	-3.86 (-5.01, -2.72), <i>P</i> < 0.001	
<i>COPD/Bronchitis/upper ARI</i>				
Overall	(<i>n</i> = 1,351), 4.6 ± 5.1	(<i>n</i> = 1,347), 2.3 ± 4.4	-2.32 (-2.68, -1.96), <i>P</i> < 0.001	
Age <75 years	(<i>n</i> = 1,067), 4.5 ± 4.7	(<i>n</i> = 1,067), 2.3 ± 4.4	-2.18 (-2.56, -1.81), <i>P</i> < 0.001	0.141
Age 75–80 years	(<i>n</i> = 122), 4.7 ± 6.2	(<i>n</i> = 123), 2.4 ± 3.8	-2.35 (-3.66, -1.05), <i>P</i> < 0.001	
Age 80–85 years	(<i>n</i> = 102), 6.1 ± 7.3	(<i>n</i> = 106), 2.2 ± 5.7	-3.79 (-5.59, -1.99), <i>P</i> < 0.001	
Age >85 years	(<i>n</i> = 60), 4.7 ± 4.9	(<i>n</i> = 51), 2.5 ± 3.6	-2.21 (-3.88, -0.53), <i>P</i> = 0.011	
<i>Sepsis/septic shock</i>				
Overall	(<i>n</i> = 2,382), 10.0 ± 9.7	(<i>n</i> = 2,405), 8.9 ± 9.1	-1.15 (-1.67, -0.63), <i>P</i> < 0.001	
Age <75 years	(<i>n</i> = 1,829), 10.1 ± 9.7	(<i>n</i> = 1,854), 8.9 ± 9.4	-1.19 (-1.79, -0.58), <i>P</i> < 0.001	0.546
Age 75–80 years	(<i>n</i> = 282), 10.6 ± 9.8	(<i>n</i> = 293), 9.1 ± 8.3	-1.36 (-2.84, 0.12), <i>P</i> = 0.072	
Age 80–85 years	(<i>n</i> = 186), 9.5 ± 7.9	(<i>n</i> = 178), 8.7 ± 7.9	-0.77 (-2.37, 0.84), <i>P</i> = 0.347	
Age >85 years	(<i>n</i> = 85), 9.1 ± 11.3	(<i>n</i> = 80), 9.0 ± 7.7	-0.46 (-3.39, 2.46), <i>P</i> = 0.755	
Subgroups by blood culture results				
<i>Blood culture negative</i>				
Overall	(<i>n</i> = 4,437), 8.1 ± 7.7	(<i>n</i> = 4,461), 6.2 ± 7.5	-1.92 (-2.23, -1.61), <i>P</i> < 0.001	
Age <75 years	(<i>n</i> = 3,365), 8.0 ± 7.8	(<i>n</i> = 3,356), 6.1 ± 7.7	-1.87 (-2.23, -1.5), <i>P</i> < 0.001	0.684
Age 75–80 years	(<i>n</i> = 467), 8.6 ± 7.9	(<i>n</i> = 494), 6.8 ± 7.2	-1.94 (-2.88, -1), <i>P</i> < 0.001	
Age 80–85 years	(<i>n</i> = 372), 8.4 ± 6.6	(<i>n</i> = 376), 6.2 ± 6.8	-2.12 (-3.06, -1.18), <i>P</i> < 0.001	
Age >85 years	(<i>n</i> = 233), 8.1 ± 5.9	(<i>n</i> = 235), 6.1 ± 5.6	-2.09 (-3.13, -1.05), <i>P</i> < 0.001	
<i>Blood culture positive</i>				
Overall	(<i>n</i> = 270), 15.6 ± 12.8	(<i>n</i> = 253), 12.7 ± 10.9	-2.92 (-4.97, -0.87), <i>P</i> = 0.005	
Age <75 years	(<i>n</i> = 186), 15.6 ± 12.1	(<i>n</i> = 172), 12.9 ± 11.8	-2.72 (-5.22, -0.21), <i>P</i> = 0.034	0.975
Age 75–80 years	(<i>n</i> = 33), 17.5 ± 14.9	(<i>n</i> = 40), 12.4 ± 8.8	-4.91 (-10.56, 0.74), <i>P</i> = 0.087	
Age 80–85 years	(<i>n</i> = 33), 13.9 ± 9.5	(<i>n</i> = 22), 12.6 ± 9.2	-1.25 (-6.59, 4.09), <i>P</i> = 0.641	
Age >85 years	(<i>n</i> = 18), 14.6 ± 19.5	(<i>n</i> = 19), 11.6 ± 8.1	-1.93 (-12.51, 8.64), <i>P</i> = 0.712	
Subgroups by setting				
<i>Treatment in the ICU</i>				
Overall	(<i>n</i> = 2,477), 9.7 ± 9.7	(<i>n</i> = 2,501), 8.6 ± 9.1	-1.11 (-1.61, -0.6), <i>P</i> < 0.001	
Age <75 years	(<i>n</i> = 1,875), 9.8 ± 9.7	(<i>n</i> = 1,911), 8.6 ± 9.4	-1.17 (-1.76, -0.58), <i>P</i> < 0.001	0.354
Age 75–80 years	(<i>n</i> = 306), 9.8 ± 9.8	(<i>n</i> = 310), 8.6 ± 8.3	-1.24 (-2.65, 0.16), <i>P</i> = 0.082	
Age 80–85 years	(<i>n</i> = 204), 8.7 ± 8.0	(<i>n</i> = 198), 7.8 ± 7.9	-0.79 (-2.26, 0.68), <i>P</i> = 0.29	
Age >85 years	(<i>n</i> = 92), 8.4 ± 11.2	(<i>n</i> = 82), 8.8 ± 7.7	-0.23 (-3.04, 2.59), <i>P</i> = 0.875	
<i>Treatment in the medical ward</i>				
Overall	(<i>n</i> = 1,729), 8.1 ± 6.2	(<i>n</i> = 1,706), 5.1 ± 5.4	-3.02 (-3.4, -2.63), <i>P</i> < 0.001	
Age <75 years	(<i>n</i> = 1,195), 7.8 ± 6.2	(<i>n</i> = 1,136), 4.9 ± 5.4	-2.89 (-3.36, -2.42), <i>P</i> < 0.001	0.242
Age 75–80 years	(<i>n</i> = 185), 8.4 ± 7.0	(<i>n</i> = 209), 5.5 ± 5.5	-3.03 (-4.26, -1.8), <i>P</i> < 0.001	
Age 80–85 years	(<i>n</i> = 194), 9.1 ± 5.9	(<i>n</i> = 191), 5.4 ± 6.0	-3.55 (-4.75, -2.36), <i>P</i> < 0.001	
Age >85 years	(<i>n</i> = 155), 8.8 ± 5.0	(<i>n</i> = 170), 5.4 ± 4.6	-3.44 (-4.49, -2.4), <i>P</i> < 0.001	
<i>Primary care treatment</i>				
Overall	(<i>n</i> = 501), 4.6 ± 4.1	(<i>n</i> = 507), 1.6 ± 3.2	-3.02 (-3.47, -2.57), <i>P</i> < 0.001	
Age <75 years	(<i>n</i> = 481), 4.6 ± 4.1	(<i>n</i> = 481), 1.6 ± 3.2	-2.97 (-3.44, -2.51), <i>P</i> < 0.001	0.611
Age 75–80 years	(<i>n</i> = 9), 6.4 ± 3.2	(<i>n</i> = 15), 1.9 ± 3.4	-4.58 (-7.49, -1.67), <i>P</i> = 0.004	
Age 80–85 years	(<i>n</i> = 7), 7.7 ± 4.2	(<i>n</i> = 9), 1.7 ± 2.5	-6.05 (-9.7, -2.4), <i>P</i> = 0.003	
Age >85 years	(<i>n</i> = 4), 3.0 ± 3.6	(<i>n</i> = 2), 3.5 ± 4.9	0.5 (-9, 10), <i>P</i> = 0.891	
Subgroups by organ failure				
<i>SOFA 0–6</i>				
Overall	(<i>n</i> = 3,747), 8.1 ± 8.0	(<i>n</i> = 3,783), 5.7 ± 7.2	-2.43 (-2.77, -2.09), <i>P</i> < 0.001	
Age <75 years	(<i>n</i> = 2,835), 7.9 ± 8.2	(<i>n</i> = 2,821), 5.5 ± 7.4	-2.41 (-2.82, -2.01), <i>P</i> < 0.001	0.93
Age 75–80 years	(<i>n</i> = 382), 8.7 ± 8.2	(<i>n</i> = 415), 6.4 ± 7.0	-2.6 (-3.64, -1.56), <i>P</i> < 0.001	
Age 80–85 years	(<i>n</i> = 319), 8.3 ± 6.6	(<i>n</i> = 321), 6.1 ± 7.2	-2.16 (-3.21, -1.11), <i>P</i> < 0.001	
Age >85 years	(<i>n</i> = 211), 8.9 ± 8.1	(<i>n</i> = 226), 6.2 ± 5.8	-2.74 (-4.04, -1.45), <i>P</i> < 0.001	
<i>SOFA 7–9</i>				
Overall	(<i>n</i> = 474), 10.1 ± 8.2	(<i>n</i> = 445), 10.2 ± 9.4	0.04 (-1.08, 1.15), <i>P</i> = 0.948	
Age <75 years	(<i>n</i> = 344), 9.9 ± 7.6	(<i>n</i> = 340), 10.4 ± 9.9	0.25 (-1.06, 1.57), <i>P</i> = 0.704	0.835
Age 75–80 years	(<i>n</i> = 62), 10.7 ± 11.4	(<i>n</i> = 55), 9.5 ± 7.0	-0.83 (-4.17, 2.5), <i>P</i> = 0.621	
Age 80–85 years	(<i>n</i> = 45), 11.4 ± 7.5	(<i>n</i> = 37), 9.3 ± 7.1	-1.95 (-5.27, 1.37), <i>P</i> = 0.245	
Age >85 years	(<i>n</i> = 23), 8.0 ± 7.4	(<i>n</i> = 13), 12.3 ± 8.1	6.36 (0.65, 12.06), <i>P</i> = 0.03	
<i>SOFA 10–24</i>				
Overall	(<i>n</i> = 486), 10.5 ± 9.1	(<i>n</i> = 486), 10.0 ± 8.8	-0.52 (-1.63, 0.59), <i>P</i> = 0.359	
Age <75 years	(<i>n</i> = 372), 10.8 ± 9.2	(<i>n</i> = 367), 10.3 ± 9.2	-0.57 (-1.88, 0.75), <i>P</i> = 0.398	0.872
Age 75–80 years	(<i>n</i> = 56), 10.7 ± 9.6	(<i>n</i> = 64), 10.9 ± 9.0	0.73 (-2.6, 4.07), <i>P</i> = 0.663	
Age 80–85 years	(<i>n</i> = 41), 10.1 ± 8.7	(<i>n</i> = 40), 7.7 ± 5.9	-1.72 (-4.98, 1.53), <i>P</i> = 0.294	
Age >85 years	(<i>n</i> = 17), 5.2 ± 3.8	(<i>n</i> = 15), 6.0 ± 3.9	0.99 (-1.94, 3.92), <i>P</i> = 0.494	

ARI, acute respiratory infection; COPD, chronic obstructive pulmonary disease. Values are presented as mean ± standard deviation. *Multivariable hierarchical regression with outcome of interest as dependent variable and trial as a random effect.




Figure 2. Forest plot showing duration of antibiotic therapy. Association of PCT-guided antibiotic stewardship and duration of antibiotic therapy in predefined subgroups. No., number.

versus 17.7 ± 23.7 days, adjusted difference 0.10, [95% CI -0.76 to 0.96], $P=0.823$ and 13.5 ± 16.1 versus 13.6 ± 16.0 days, adjusted difference -0.01 , [95% CI -0.88 to 0.86], $P=0.983$) (Appendices 4 and 5). This finding was consistent throughout most subgroups without evidence for a subgroup effect (P for interaction ≥ 0.05 each), but there was evidence for a subgroup effect regarding length of ICU stay overall (P interaction = 0.014), in patients with septic shock (P interaction = 0.013), in patients with negative cultures (P interaction = 0.013), in ICU patients (P interaction = 0.013) and in patients with SOFA scores of 0–6 points (P interaction = 0.005).

Discussion

The main findings of this meta-analysis including individual patient data from 9,421 participants from 28 RCTs are 2-fold. First, regarding efficacy of PCT-guided antibiotic stewardship, we found a significant reduction of antibiotic exposure due to shorter antibiotic treatment durations in PCT-guided patients in all age groups and in all subgroups stratified by infection diagnosis, blood culture results, setting and sepsis severity. Second, regarding safety, our overall analysis showed a significant reduction in mortality in PCT-guided patients compared to control group patients with again no evidence for higher mortality based on age groups overall and within subgroups. Different subgroup analyses showed similar results. These data support the use of PCT also in the very old patient as an effective mean to lowering antibiotic exposure with no apparent harmful effects on mortality.

These data are reassuring as it remained unclear whether biomarkers of infection would have a similar clinical impact in older patients compared to younger patients due to known differences in the expression of cytokines resulting from bacterial infection [26, 27]. Thus, safety of using a biomarker

for decision-making regarding antibiotic treatment in the very old patient population is paramount and has not yet been well documented as most previous RCTs did not focus on this specific patient population. Herein, our individual patient data meta-analysis provides important information in this regard.

Our analysis supporting the use of PCT in older patients is in line with several previous studies [44–46]. In a previous prospective observational study comparing different biomarkers and clinical signs in infected and uninfected patients in a geriatric teaching hospital in Switzerland, PCT was found to have high specificity towards infection but had an overall suboptimal performance [44]. Yet, due to the lack of a true reference standard for infection, the observational design may mask patients with true infection but negative cultures. Randomized research, however, may help to overcome this limitation by focusing on the effectiveness of the strategy regarding antibiotic consumption and clinical outcomes.

For this analysis, we pooled individual patient data from different trials. Trials differed in regard to the patient population (e.g. respiratory infection, general sepsis), setting (e.g. emergency room, medical ward, ICU) and type of PCT protocol used (e.g. recommendation regarding initiation versus stop of therapy) with also different cut-offs (e.g. $0.25 \mu\text{g/l}$ in lower risk settings versus 0.5 in higher risk settings). We have previously compared different PCT protocols and found PCT to be most helpful when used for early stopping antibiotic treatment, particularly in the setting of high patients such as patients with positive blood cultures, using the $0.25 \mu\text{g/l}$ cut-off for the emergency room setting and $0.5 \mu\text{g/l}$ for the ICU setting [43].

Adherence in trials was variable regarding following the PCT algorithm with lower adherence in ICU trials with higher risk patients. Interestingly, the difference in duration of antibiotic treatment between PCT-guided patients and control patients was lower in the ICU setting (-1.1 days)

Table 2. Secondary endpoint defined as mortality within 30 days overall and stratified by age, diagnosis, blood culture results, setting and sepsis severity

	Control (no. of events/no. of control group)	PCT (no. of events/no. of PCT group)	Adjusted OR* (95% CI), <i>P</i> value	<i>P</i> for interaction
30-day mortality, <i>n</i> (%)				
Subgroups by age				
Overall	599/4707 (12.7)	543/4714 (11.5)	0.90 (0.81, 1.00), <i>P</i> = 0.046	
Age <75 years	378/3551 (10.6)	331/3528 (9.4)	0.87 (0.76, 1.00), <i>P</i> = 0.047	0.891
Age 75–80 years	93/500 (18.6)	89/534 (16.7)	0.86 (0.67, 1.10), <i>P</i> = 0.216	
Age 80–85 years	72/405 (17.8)	81/398 (20.4)	1.19 (0.91, 1.55), <i>P</i> = 0.211	
Age >85 years	56/251 (22.3)	42/254 (16.5)	0.76 (0.55, 1.06), <i>P</i> = 0.104	
Subgroups by diagnosis				
<i>Pneumonia</i>				
Overall	49/974 (5.0)	45/962 (4.7)	0.92 (0.6, 1.39), <i>P</i> = 0.678	
Age <75 years	19/655 (2.9)	13/607 (2.1)	0.70 (0.34, 1.44), <i>P</i> = 0.337	0.833
Age 75–80 years	5/96 (5.2)	11/118 (9.3)	1.85 (0.61, 5.60), <i>P</i> = 0.276	
Age 80–85 years	13/117 (11.1)	10/114 (8.8)	0.81 (0.34, 1.96), <i>P</i> = 0.647	
Age >85 years	12/106 (11.3)	11/123 (8.9)	0.76 (0.32, 1.82), <i>P</i> = 0.538	
<i>COPD/bronchitis/lupper ARI</i>				
Overall	18/1351 (1.3)	21/1347 (1.6)	1.21 (0.63, 2.29), <i>P</i> = 0.568	
Age <75 years	8/1067 (0.7)	9/1067 (0.8)	1.16 (0.44, 3.07), <i>P</i> = 0.768	0.634
Age 75–80 years	0/122 (0.0)	3/123 (2.4)	NA	
Age 80–85 years	3/102 (2.9)	4/106 (3.8)	1.29 (0.28, 5.97), <i>P</i> = 0.746	
Age >85 years	7/60 (12)	5/51 (10)	0.78 (0.23, 2.66), <i>P</i> = 0.694	
<i>Sepsis/septic shock</i>				
Overall	532/2382 (22.3)	477/2405 (19.8)	0.86 (0.75, 0.99), <i>P</i> = 0.038	
Age <75 years	351/1829 (19.2)	309/1854 (16.7)	0.85 (0.72, 1), <i>P</i> = 0.054	0.57
Age 75–80 years	88/282 (31.2)	75/293 (25.6)	0.73 (0.5, 1.05), <i>P</i> = 0.089	
Age 80–85 years	56/186 (30.1)	67/178 (37.6)	1.45 (0.93, 2.27), <i>P</i> = 0.102	
Age >85 years	37/85 (44)	26/80 (33)	0.63 (0.32, 1.23), <i>P</i> = 0.178	
Subgroups by blood culture results				
<i>Blood culture negative</i>				
Overall	546/4437 (12.3)	504/4461 (11.3)	0.91 (0.8, 1.03), <i>P</i> = 0.146	
Age <75 years	340/3365 (10.1)	308/3356 (9.2)	0.91 (0.77, 1.07), <i>P</i> = 0.268	0.947
Age 75–80 years	87/467 (18.6)	79/494 (16.0)	0.75 (0.53, 1.06), <i>P</i> = 0.104	
Age 80–85 years	66/372 (17.7)	77/376 (20.5)	1.24 (0.85, 1.79), <i>P</i> = 0.263	
Age >85 years	53/233 (22.7)	40/235 (17.0)	0.65 (0.41, 1.04), <i>P</i> = 0.07	
<i>Blood culture positive</i>				
Overall	53/270 (19.6)	39/253 (15.4)	0.7 (0.44, 1.11), <i>P</i> = 0.13	
Age <75 years	38/186 (20.4)	23/172 (13.4)	0.56 (0.31, 0.99), <i>P</i> = 0.046	0.519
Age 75–80 years	6/33 (18)	10/40 (25)	1.59 (0.49, 5.15), <i>P</i> = 0.438	
Age 80–85 years	6/33 (18)	4/22 (18)	0.68 (0.15, 3.11), <i>P</i> = 0.622	
Age >85 years	3/18 (17)	2/19 (11)	1.07 (0.13, 8.79), <i>P</i> = 0.952	
Subgroups by setting				
<i>Treatment in the ICU</i>				
Overall	532/2477 (21.5)	477/2501 (19.1)	0.86 (0.75, 0.99), <i>P</i> = 0.038	
Age <75 years	351/1875 (18.7)	309/1911 (16.2)	0.85 (0.71, 1), <i>P</i> = 0.051	0.430
Age 75–80 years	88/306 (28.8)	75/310 (24.2)	0.73 (0.5, 1.05), <i>P</i> = 0.092	
Age 80–85 years	56/204 (27.5)	67/198 (33.8)	1.36 (0.88, 2.09), <i>P</i> = 0.165	
Age >85 years	37/92 (40)	26/82 (32)	0.66 (0.34, 1.28), <i>P</i> = 0.218	
<i>Treatment in the medical ward</i>				
Overall	66/1729 (3.8)	66/1706 (3.9)	1.01 (0.71, 1.44), <i>P</i> = 0.937	
Age <75 years	27/1195 (2.3)	22/1136 (1.9)	0.85 (0.48, 1.5), <i>P</i> = 0.566	0.709
Age 75–80 years	5/185 (2.7)	14/209 (6.7)	2.49 (0.87, 7.18), <i>P</i> = 0.09	
Age 80–85 years	16/194 (8.2)	14/191 (7.3)	0.93 (0.44, 1.98), <i>P</i> = 0.854	
Age >85 years	18/155 (11.6)	16/170 (9.4)	0.77 (0.38, 1.58), <i>P</i> = 0.477	
Subgroups by organ failure				
<i>SOFA 0–6</i>				
Overall	303/3747 (8.1)	292/3783 (7.7)	0.95 (0.8, 1.12), <i>P</i> = 0.531	
Age <75 years	183/2835 (6.5)	166/2821 (5.9)	0.91 (0.73, 1.13), <i>P</i> = 0.406	0.862
Age 75–80 years	47/382 (12.3)	51/415 (12.3)	0.9 (0.59, 1.39), <i>P</i> = 0.648	
Age 80–85 years	39/319 (12.2)	45/321 (14.0)	1.22 (0.77, 1.95), <i>P</i> = 0.397	
Age >85 years	34/211 (16.1)	30/226 (13.3)	0.75 (0.43, 1.28), <i>P</i> = 0.285	
<i>SOFA 7–9</i>				
Overall	108/474 (22.8)	92/445 (20.7)	0.9 (0.65, 1.23), <i>P</i> = 0.504	
Age <75 years	62/344 (18.0)	62/40 (18.2)	1.06 (0.71, 1.56), <i>P</i> = 0.785	0.984
Age 75–80 years	25/62 (40)	12/55 (22)	0.4 (0.17, 0.92), <i>P</i> = 0.031	
Age 80–85 years	12/45 (27)	13/37 (35)	1.43 (0.54, 3.77), <i>P</i> = 0.469	
Age >85 years	9/23 (39)	5/13 (38)	1.25 (0.26, 5.96), <i>P</i> = 0.776	
<i>SOFA 10–24</i>				
Overall	188/486 (38.7)	159/486 (32.7)	0.77 (0.59, 1), <i>P</i> = 0.049	
Age <75 years	133/372 (35.8)	103/367 (28.1)	0.7 (0.51, 0.96), <i>P</i> = 0.026	0.684
Age 75–80 years	21/56 (38)	26/64 (41)	1.07 (0.5, 2.27), <i>P</i> = 0.858	
Age 80–85 years	21/41 (51)	23/40 (57)	1.14 (0.45, 2.89), <i>P</i> = 0.785	
Age >85 years	13/17 (76)	7/15 (47)	0.31 (0.07, 1.47), <i>P</i> = 0.14	

ARI, acute respiratory infection; COPD, chronic obstructive pulmonary disease; NA, not applicable. Values are presented as *n* (%). *Multivariable hierarchical regression with outcome of interest as dependent variable and trial as a random effect.




Figure 3. Forest plot showing 30-day mortality. Association of PCT-guided antibiotic stewardship and mortality in predefined subgroups. No., number.

compared to treatments in the medical ward (−3.0 days) or to the primary care treatment (−3.0 days). These differences may be explained by adherence to the PCT algorithm.

The strength of this meta-analysis includes a predefined study protocol, a comprehensive search and retrieval of all relevant trials, and a network that permitted inclusion of individual patient data from most eligible trials. We also standardized outcome definitions across trials and performed appropriate subgroup and sensitivity analyses, thereby overcoming the limitations of previous meta-analyses with aggregated data to allow more definitive conclusions. To our knowledge, this is the first analysis addressing the effects of PCT guidance in patients within different age group. There is some overlap with previous secondary reports from the same database particularly regarding description of trials and methodology used for analysis [21, 22, 28, 34, 35]. The focus on age groups regarding effects of PCT use, however, is novel and has not been done in previous reports. There are also some limitations to our study. First, we limited our data to immunocompetent adults and patients not being on haemodialysis before inclusion, thereby reducing generalizability of our conclusions to other patient populations. Also, typically, trial inclusion focuses on less severely ill old patients who will not die instantly thereby potentially neglecting older patients with higher severity of illness, again introducing selection bias. Second, the heterogeneity of our patient population with regard to focus of infection, clinical setting and disease severity also limits generalizability of results, in particular with regard to the primary endpoint mortality. Third, the adherence to the PCT protocols among the studies varied widely from 44 to 97%. Overall, adherence rates were better in low-risk populations, whereas the adherence in high-risk patients was lower. Also, we had a limited number of patients in the oldest old age group, which was particularly true for the ICU setting. We also had very limited data on important prognostic factors such

as nutrition and functional status, comorbidities and other heterogenic parameters of the oldest old population. Thus, specific trials in these particularly vulnerable patient populations are needed. Also, we had limited data on PCT kinetics and are thus not able to understand whether PCT levels behave differently according to age group of patients. Finally, this analysis is based on a systematic search and meta-analysis done in collaboration with Cochrane in 2017 and updated in February 2018, and more recent trials have not yet been included. An update of the overall analysis is planned in 2021 with results expected within 6–12 months. Most trials used the same PCT assay (Kryptor PCT; Brahms, Hennigsdorf, Germany), but today several other commercial PCT assay exist today with comparable results [47]. Finally, in our subgroup, analysis of age was based on chronological age and the use of biological age might would reveal different results.

Conclusions

In conclusion, this large individual patient data meta-analysis confirms that PCT-guided antibiotic treatment in older patients is associated with significantly reduced antibiotic exposures and no increase in mortality. Specific trials focusing on infections in the oldest old populations should be endorsed to safely reduce antibiotic consumptions in this particularly vulnerable population of patients.

Supplementary Data: Supplementary data mentioned in the text are available to subscribers in *Age and Ageing* online.

Acknowledgments: We thank all researchers and patients involved in the individual trials for sharing their data.

Declaration of Conflicts of Interest: P.S. and B.M. report receiving grants from Thermo Fisher Scientific, Roche Diagnostics and bioMérieux. C.-E.L. received lecture fees

from Thermo Fisher Scientific B·R·A·H·M·S GmbH, bioMérieux. Y.S. has received unrestricted research grants from Thermo Fisher Scientific, bioMérieux, Orion Pharma and Pfizer. M.C.-C., D.S. and M.T. have received research support from Thermo Fisher Scientific. All other authors declare that they have no conflicts of interest. The National Institute for Health Research provided a grant for the initial Cochrane analysis. Roche Diagnostics provided an unrestricted research grant for this analysis. The funders of the study had no bearing on study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Declaration of Sources of Funding: This work was supported by Thermo Fisher Scientific.

References

- Shehabi Y, Sterba M, Garrett PM *et al*. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. *Am J Respir Crit Care Med* 2014; 190: 1102–10.
- Rhodes A, Evans LE, Alhazzani W *et al*. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med* 2017; 43: 304–77.
- Kumar A, Ellis P, Arabi Y *et al*. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest* 2009; 136: 1237–48.
- Gregoriano C, Heilmann E, Molitor A, Schuetz P. Role of procalcitonin use in the management of sepsis. *J Thorac Dis* 2020; 12: S5–15.
- Neeser O, Branche A, Mueller B, Schuetz P. How to: implement procalcitonin testing in my practice. *Clin Microbiol Infect* 2019; 25: 1226–30.
- Branche A, Neeser O, Mueller B, Schuetz P. Procalcitonin to guide antibiotic decision making. *Curr Opin Infect Dis* 2019; 32: 130–5.
- Schuetz P, Birkhahn R, Sherwin R *et al*. Serial procalcitonin predicts mortality in severe sepsis patients: results from the Multicenter Procalcitonin Monitoring Sepsis (MOSES) study. *Crit Care Med* 2017; 45: 781–9.
- Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. *Lancet Infect Dis* 2013; 13: 426–35.
- Mitsuma SF, Mansour MK, Dekker JP *et al*. Promising new assays and technologies for the diagnosis and management of infectious diseases. *Clin Infect Dis* 2013; 56: 996–1002.
- Annan D, Maxime V, Faller JP *et al*. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. *BMJ Open* 2013; 3:e002186. doi: 10.1136/bmjopen-2012-002186.
- Bloos F, Trips E, Nierhaus A *et al*. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. *JAMA Intern Med* 2016; 176: 1266–76.
- Bouadma L, Luyt CE, Tubach F *et al*. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *Lancet* 2010; 375: 463–74.
- de Jong E, van Oers JA, Beishuizen A *et al*. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. *Lancet Infect Dis* 2016; 16: 819–27.
- Deliberato RO, Marra AR, Sanches PR *et al*. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. *Diagn Microbiol Infect Dis* 2013; 76: 266–71.
- Hochreiter M, Schroeder S. Procalcitonin-based algorithm. Management of antibiotic therapy in critically ill patients. *Anaesthesist* 2011; 60: 661–73.
- Schroeder S, Hochreiter M, Koehler T *et al*. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. *Langenbeck's archives of surgery/Deutsche Gesellschaft fur. Chirurgie* 2009; 394: 221–6.
- Hochreiter M, Kohler T, Schweiger AM *et al*. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. *Crit Care* 2009; 13: R83.
- Layios N, Lambermont B, Canivet JL *et al*. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. *Crit Care Med* 2012; 40: 2304–9.
- Oliveira CF, Botoni FA, Oliveira CR *et al*. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. *Crit Care Med* 2013; 41: 2336–43.
- Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. *Am J Respir Crit Care Med* 2008; 177: 498–505.
- Wirz Y, Meier MA, Bouadma L *et al*. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. *Crit Care* 2018; 22: 191.
- Schuetz P, Wirz Y, Sager R *et al*. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev* 2017; 10: CD007498.
- Schuetz P, Briel M, Christ-Crain M *et al*. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. *Clin Infect Dis* 2012; 55: 651–62.
- Schuetz P, Christ-Crain M, Thomann R *et al*. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the pro HOSP randomized controlled trial. *JAMA* 2009; 302: 1059–66.
- Schuetz P, Briel M, Christ-Crain M, Wolbers M, Stolz D, Tamm M *et al*. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev*. 2008. <https://doi.org/10.1002/14651858.CD007498>.
- Fuentes E, Fuentes M, Alarcon M, Palomo I. Immune system dysfunction in the elderly. *An Acad Bras Cienc* 2017; 89: 285–99.

E. Heilmann *et al.*

27. Ticinesi A, Lauretani F, Nouvenne A *et al.* C-reactive protein (CRP) measurement in geriatric patients hospitalized for acute infection. *Eur J Intern Med* 2017; 37: 7–12.
28. Heilmann E, Gregoriano C, Wirz Y *et al.* Association of kidney function with effectiveness of procalcitonin-guided antibiotic treatment: a patient-level meta-analysis from randomized controlled trials. *Clin Chem Lab Med* 2020.
29. Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. *Eur Respir J* 2011; 37: 1439–46.
30. Schuetz P, Christ-Crain M, Muller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. *Curr Opin Crit Care* 2007; 13: 578–85.
31. Gavazzi G, FoR H, Stucker F, Graf JD, Michel JP, Krause KH. Response letter to Christ-Crain and MÄLLer. *J Am Geriatr Soc* 2006; 54: 546–8.
32. Iankova I, Thompson-Leduc P, Kirson NY *et al.* Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and meta-analysis. *Crit Care Med* 2018; 46: 691–8.
33. Andriolo BN, Andriolo RB, Salomao R, Atallah AN. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock. *Cochrane Database Syst Rev* 2017; 1: CD010959.
34. Schuetz P, Wirz Y, Sager R *et al.* Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. *Lancet Infect Dis* 2018; 18: 95–107.
35. Meier MA, Branche A, Neeser OL *et al.* Procalcitonin-guided antibiotic treatment in patients with positive blood cultures: a patient-level meta-analysis of randomized trials. *Clin Infect Dis* 2019; 69: 388–96.
36. Kutz A, Briel M, Christ-Crain M *et al.* Prognostic value of procalcitonin in respiratory tract infections across clinical settings. *Crit Care* 2015; 19: 74.
37. Schuetz P, Muller B, Christ-Crain M *et al.* Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev* 2012; 9: Cd007498.
38. Stewart LA, Clarke M, Rovers M *et al.* Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. *JAMA* 2015; 313: 1657–65.
39. Liberati A, Altman DG, Tetzlaff J *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ (Clin Res Ed)* 2009; b2700: 339.
40. Guyatt GH, Oxman AD, Vist GE *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336: 924–6.
41. Thompson SG, Turner RM, Warn DE. Multilevel models for meta-analysis, and their application to absolute risk differences. *Stat Methods Med Res* 2001; 10: 375–92.
42. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. *Stat Med* 2000; 19: 3417–32.
43. Schuetz P, Bolliger R, Merker M *et al.* Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. *Expert Rev Anti-Infect Ther* 2018; 16: 555–64.
44. Stucker F, Herrmann F, Graf JD, Michel JP, Krause KH, Gavazzi G. Procalcitonin and infection in elderly patients. *J Am Geriatr Soc* 2005; 53: 1392–5.
45. Falcone M, Paul M, Yahav D *et al.* Antimicrobial consumption and impact of antimicrobial stewardship programmes in long-term care facilities. *Clin Microbiol Infect* 2019; 25: 562–9.
46. Saeed K, Gonzalez Del Castillo J, Backous C *et al.* Hot topics on procalcitonin use in clinical practice, can it help antibiotic stewardship? *Int J Antimicrob Agents* 2019; 54: 686–96.
47. Schuetz P, Bretscher C, Bernasconi L, Mueller B. Overview of procalcitonin assays and procalcitonin-guided protocols for the management of patients with infections and sepsis. *Expert Rev Mol Diagn* 2017; 17: 593–601.

Received 30 October 2020; editorial decision 19 April 2021